ReviewBladder cancer (Amsterdam, Netherlands)2016
Circulating Biomarkers in Bladder Cancer.
Review in Bladder cancer (Amsterdam, Netherlands), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Urinary transcript quantitation of CK20 and IGF2 for the non-invasive bladder cancer detection.Journal of cancer research and clinical oncology · 2017Trial
- LINC00332 as a potential diagnostic marker for the low-grade tumors in renal cell carcinoma patients.BMC urology · 2025Article
- Comprehensive Mendelian randomization and colocalization analysis of plasma proteomics to identify new therapeutic targets for bladder cancer.Journal of Cancer · 2025Article
- Evaluating for Correlations between Specific Metabolites in Patients Receiving First-Line or Second-Line Immunotherapy for Metastatic or Recurrent NSCLC: An Exploratory Study Based on Two Cohorts.Molecular cancer therapeutics · 2024Article
- Discovery of novel serum metabolic biomarkers in patients with polycystic ovarian syndrome and premature ovarian failure.Bioengineered · 2021Article
- Fatty Acid Metabolism Reprogramming in Advanced Prostate Cancer.Metabolites · 2021Review
- PUM1 and RNase P genes as potential cell-free DNA markers in breast cancer.Journal of clinical laboratory analysis · 2021Article
- Serum Metabolic Profiling Identifies a Biomarker Panel for Improvement of Prostate Cancer Diagnosis.Frontiers in oncology · 2021Article
- Limited utility of qPCR-based detection of tumor-specific circulating mRNAs in whole blood from clear cell renal cell carcinoma patients.BMC urology · 2020Article
- An EMT-related gene signature for the prognosis of human bladder cancer.Journal of cellular and molecular medicine · 2020Article
- Circulating Non-coding RNAs in Renal Cell Carcinoma-Pathogenesis and Potential Implications as Clinical Biomarkers.Frontiers in cell and developmental biology · 2020Review
- Development and Validation of a Nine-Redox-Related Long Noncoding RNA Signature in Renal Clear Cell Carcinoma.Oxidative medicine and cellular longevity · 2020Article
- Improving the diagnosis of high grade and stage bladder cancer by detecting increased urinary calprotectin expression in tumor tissue and tumor-associated inflammatory response.Investigative and clinical urology · 2019Article
- The current role of circulating biomarkers in non-muscle invasive bladder cancer.Translational andrology and urology · 2019Review
- Molecularly-driven precision medicine for advanced bladder cancer.World journal of urology · 2018Review
- A risk score staging system based on the expression of seven genes predicts the outcome of bladder cancer.Oncology letters · 2018Article
- Developments in Point-of-Care Diagnostic Technology for Cancer Detection.Diagnostics (Basel, Switzerland) · 2018Review
- A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma.Hepatology (Baltimore, Md.) · 2018Article
- Article
- Identification of Biomarkers Correlated with the TNM Staging and Overall Survival of Patients with Bladder Cancer.Frontiers in physiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer is a molecularly heterogeneous disease characterized by multiple unmet needs in the realm of diagnosis, clinical staging, monitoring and therapy. There is an urgent need to develop precision medicine for advanced urothelial carcinoma. Given the difficulty of serial analyses of metastatic tumor tissue to identify resistance and new therapeutic targets, development of non-invasive monitoring using circulating molecular biomarkers is critically important. Although the development of circulating biomarkers for the management of bladder cancer is in its infancy and may currently suffer from lower sensitivity of detection, they have inherent advantages owing to non-invasiveness. Additionally, circulating molecular alterations may capture tumor heterogeneity without the sampling bias of tissue biopsy. This review describes the accumulating data to support further development of circulating biomarkers including circulating tumor cells, cell-free circulating tumor (ct)-DNA, RNA, micro-RNA and proteomics to improve the management of bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.